Laboratory and clinical studies of temafloxacin

Y. Irabu, H. Fukuhara, H. Nakamura, H. Kaneshima, K. Simoji, K. Kitsukawa, Y. Sigeno, A. Saito, K. Furugen, I. Nakasone, S. Taira, Nobuchika Kusano, S. Hokama, T. Simoji, T. Ohyama

Research output: Contribution to journalArticle

Abstract

We performed laboratory and clinical evaluations of temafloxacin (TMFX), a new oral trifluorinated quinolone, with the following results. 1) Antimicrobial activity. The minimum inhibitory concentrations (MICs) of TMFX for a total of 307 clinically isolated strains, were determined and compared with those of ofloxacin, tosufloxacin, ciprofloxacin, enoxacin and norfloxacin using the MIC-2000 system. TMFX had broad antimicrobial activities against all clinically isolated strains except methicillin-resistant Staphylococcus aureus (MRSA), Serratia marcescens and Pseudomonas aeruginosa. 2) Clinical efficacy TMFX, 150 mg x 2 (300 mg/day), was given to 2 patients with chronic bronchitis. Two patients with acute bronchitis and 4 with chronic bronchitis were treated with TMFX, 300 mg x 2 (600 mg/day). Clinical responses were good in all 8 patients. One strain of Haemophilus influenzae was eradicated while one strain of P. aeruginosa was not. No side effects were observed, but abnormal laboratory findings, including slight elevations in GOT, GPT and eosinophils, were observed in 2 patients.

Original languageEnglish
Pages (from-to)458-463
Number of pages6
JournalChemotherapy
Volume41
Issue numberSUPPL. 5
Publication statusPublished - 1993
Externally publishedYes

Fingerprint

temafloxacin
Chronic Bronchitis
Microbial Sensitivity Tests
tosufloxacin
Pseudomonas aeruginosa
Enoxacin
Norfloxacin
Serratia marcescens
Ofloxacin
Bronchitis
Quinolones
Haemophilus influenzae
Methicillin-Resistant Staphylococcus aureus
Ciprofloxacin
Eosinophils
Clinical Studies

ASJC Scopus subject areas

  • Pharmacology

Cite this

Irabu, Y., Fukuhara, H., Nakamura, H., Kaneshima, H., Simoji, K., Kitsukawa, K., ... Ohyama, T. (1993). Laboratory and clinical studies of temafloxacin. Chemotherapy, 41(SUPPL. 5), 458-463.

Laboratory and clinical studies of temafloxacin. / Irabu, Y.; Fukuhara, H.; Nakamura, H.; Kaneshima, H.; Simoji, K.; Kitsukawa, K.; Sigeno, Y.; Saito, A.; Furugen, K.; Nakasone, I.; Taira, S.; Kusano, Nobuchika; Hokama, S.; Simoji, T.; Ohyama, T.

In: Chemotherapy, Vol. 41, No. SUPPL. 5, 1993, p. 458-463.

Research output: Contribution to journalArticle

Irabu, Y, Fukuhara, H, Nakamura, H, Kaneshima, H, Simoji, K, Kitsukawa, K, Sigeno, Y, Saito, A, Furugen, K, Nakasone, I, Taira, S, Kusano, N, Hokama, S, Simoji, T & Ohyama, T 1993, 'Laboratory and clinical studies of temafloxacin', Chemotherapy, vol. 41, no. SUPPL. 5, pp. 458-463.
Irabu Y, Fukuhara H, Nakamura H, Kaneshima H, Simoji K, Kitsukawa K et al. Laboratory and clinical studies of temafloxacin. Chemotherapy. 1993;41(SUPPL. 5):458-463.
Irabu, Y. ; Fukuhara, H. ; Nakamura, H. ; Kaneshima, H. ; Simoji, K. ; Kitsukawa, K. ; Sigeno, Y. ; Saito, A. ; Furugen, K. ; Nakasone, I. ; Taira, S. ; Kusano, Nobuchika ; Hokama, S. ; Simoji, T. ; Ohyama, T. / Laboratory and clinical studies of temafloxacin. In: Chemotherapy. 1993 ; Vol. 41, No. SUPPL. 5. pp. 458-463.
@article{5857961737d9496a81e8c973c22f4f6b,
title = "Laboratory and clinical studies of temafloxacin",
abstract = "We performed laboratory and clinical evaluations of temafloxacin (TMFX), a new oral trifluorinated quinolone, with the following results. 1) Antimicrobial activity. The minimum inhibitory concentrations (MICs) of TMFX for a total of 307 clinically isolated strains, were determined and compared with those of ofloxacin, tosufloxacin, ciprofloxacin, enoxacin and norfloxacin using the MIC-2000 system. TMFX had broad antimicrobial activities against all clinically isolated strains except methicillin-resistant Staphylococcus aureus (MRSA), Serratia marcescens and Pseudomonas aeruginosa. 2) Clinical efficacy TMFX, 150 mg x 2 (300 mg/day), was given to 2 patients with chronic bronchitis. Two patients with acute bronchitis and 4 with chronic bronchitis were treated with TMFX, 300 mg x 2 (600 mg/day). Clinical responses were good in all 8 patients. One strain of Haemophilus influenzae was eradicated while one strain of P. aeruginosa was not. No side effects were observed, but abnormal laboratory findings, including slight elevations in GOT, GPT and eosinophils, were observed in 2 patients.",
author = "Y. Irabu and H. Fukuhara and H. Nakamura and H. Kaneshima and K. Simoji and K. Kitsukawa and Y. Sigeno and A. Saito and K. Furugen and I. Nakasone and S. Taira and Nobuchika Kusano and S. Hokama and T. Simoji and T. Ohyama",
year = "1993",
language = "English",
volume = "41",
pages = "458--463",
journal = "Chemotherapy",
issn = "0009-3165",
publisher = "S. Karger AG",
number = "SUPPL. 5",

}

TY - JOUR

T1 - Laboratory and clinical studies of temafloxacin

AU - Irabu, Y.

AU - Fukuhara, H.

AU - Nakamura, H.

AU - Kaneshima, H.

AU - Simoji, K.

AU - Kitsukawa, K.

AU - Sigeno, Y.

AU - Saito, A.

AU - Furugen, K.

AU - Nakasone, I.

AU - Taira, S.

AU - Kusano, Nobuchika

AU - Hokama, S.

AU - Simoji, T.

AU - Ohyama, T.

PY - 1993

Y1 - 1993

N2 - We performed laboratory and clinical evaluations of temafloxacin (TMFX), a new oral trifluorinated quinolone, with the following results. 1) Antimicrobial activity. The minimum inhibitory concentrations (MICs) of TMFX for a total of 307 clinically isolated strains, were determined and compared with those of ofloxacin, tosufloxacin, ciprofloxacin, enoxacin and norfloxacin using the MIC-2000 system. TMFX had broad antimicrobial activities against all clinically isolated strains except methicillin-resistant Staphylococcus aureus (MRSA), Serratia marcescens and Pseudomonas aeruginosa. 2) Clinical efficacy TMFX, 150 mg x 2 (300 mg/day), was given to 2 patients with chronic bronchitis. Two patients with acute bronchitis and 4 with chronic bronchitis were treated with TMFX, 300 mg x 2 (600 mg/day). Clinical responses were good in all 8 patients. One strain of Haemophilus influenzae was eradicated while one strain of P. aeruginosa was not. No side effects were observed, but abnormal laboratory findings, including slight elevations in GOT, GPT and eosinophils, were observed in 2 patients.

AB - We performed laboratory and clinical evaluations of temafloxacin (TMFX), a new oral trifluorinated quinolone, with the following results. 1) Antimicrobial activity. The minimum inhibitory concentrations (MICs) of TMFX for a total of 307 clinically isolated strains, were determined and compared with those of ofloxacin, tosufloxacin, ciprofloxacin, enoxacin and norfloxacin using the MIC-2000 system. TMFX had broad antimicrobial activities against all clinically isolated strains except methicillin-resistant Staphylococcus aureus (MRSA), Serratia marcescens and Pseudomonas aeruginosa. 2) Clinical efficacy TMFX, 150 mg x 2 (300 mg/day), was given to 2 patients with chronic bronchitis. Two patients with acute bronchitis and 4 with chronic bronchitis were treated with TMFX, 300 mg x 2 (600 mg/day). Clinical responses were good in all 8 patients. One strain of Haemophilus influenzae was eradicated while one strain of P. aeruginosa was not. No side effects were observed, but abnormal laboratory findings, including slight elevations in GOT, GPT and eosinophils, were observed in 2 patients.

UR - http://www.scopus.com/inward/record.url?scp=0027730006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027730006&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0027730006

VL - 41

SP - 458

EP - 463

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3165

IS - SUPPL. 5

ER -